JP2021519308A5 - - Google Patents

Info

Publication number
JP2021519308A5
JP2021519308A5 JP2020551963A JP2020551963A JP2021519308A5 JP 2021519308 A5 JP2021519308 A5 JP 2021519308A5 JP 2020551963 A JP2020551963 A JP 2020551963A JP 2020551963 A JP2020551963 A JP 2020551963A JP 2021519308 A5 JP2021519308 A5 JP 2021519308A5
Authority
JP
Japan
Prior art keywords
alkyl
groups
cancer
alkoxy
haloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020551963A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021519308A (ja
JP7387627B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/024976 external-priority patent/WO2019191667A1/en
Publication of JP2021519308A publication Critical patent/JP2021519308A/ja
Publication of JP2021519308A5 publication Critical patent/JP2021519308A5/ja
Application granted granted Critical
Publication of JP7387627B2 publication Critical patent/JP7387627B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020551963A 2018-03-29 2019-03-29 転写活性化タンパク質のイミダゾピペラジン阻害剤 Active JP7387627B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862650151P 2018-03-29 2018-03-29
US62/650,151 2018-03-29
PCT/US2019/024976 WO2019191667A1 (en) 2018-03-29 2019-03-29 Imidazopiperazine inhibitors of transcription activating proteins

Publications (3)

Publication Number Publication Date
JP2021519308A JP2021519308A (ja) 2021-08-10
JP2021519308A5 true JP2021519308A5 (cg-RX-API-DMAC7.html) 2022-03-30
JP7387627B2 JP7387627B2 (ja) 2023-11-28

Family

ID=68057632

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020551963A Active JP7387627B2 (ja) 2018-03-29 2019-03-29 転写活性化タンパク質のイミダゾピペラジン阻害剤

Country Status (12)

Country Link
US (3) US11058688B2 (cg-RX-API-DMAC7.html)
EP (1) EP3773587A4 (cg-RX-API-DMAC7.html)
JP (1) JP7387627B2 (cg-RX-API-DMAC7.html)
KR (1) KR102815607B1 (cg-RX-API-DMAC7.html)
CN (1) CN112165944B (cg-RX-API-DMAC7.html)
AU (2) AU2019245403B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020019824A2 (cg-RX-API-DMAC7.html)
CA (1) CA3095367A1 (cg-RX-API-DMAC7.html)
IL (1) IL277628A (cg-RX-API-DMAC7.html)
RU (1) RU2020131507A (cg-RX-API-DMAC7.html)
WO (1) WO2019191667A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202006092B (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3095367A1 (en) 2018-03-29 2019-10-03 Board Of Regents, The University Of Texas System Imidazopiperazine inhibitors of transcription activating proteins
WO2019195846A1 (en) 2018-04-06 2019-10-10 Board Of Regents, The University Of Texas System Imidazopiperazinone inhibitors of transcription activating proteins
US12486251B2 (en) 2020-04-25 2025-12-02 Pharmablock Sciences (Nanjing) , Inc. CBP/EP300 inhibitor and use thereof
KR20230080441A (ko) * 2020-10-02 2023-06-07 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 전사 활성화 단백질의 이미다조피페라진 억제제
JP7777131B2 (ja) * 2020-10-02 2025-11-27 ボード オブ レジェンツ,ザ ユニバーシティ オブ テキサス システム 転写活性化タンパク質のイミダゾピペラジン阻害剤
US20240122941A1 (en) * 2020-12-25 2024-04-18 National Cancer Center Therapy based on synthetic lethality in swi/snf complex-dysfunction cancer
JP7746406B2 (ja) * 2021-04-21 2025-09-30 長春金賽薬業有限責任公司 イミダゾール含有縮合環系誘導体、その調製方法及びその医薬上の応用
CN113429427A (zh) * 2021-07-05 2021-09-24 湖南南新制药股份有限公司 杂环化合物及其制备方法和药物用途
CA3228746A1 (en) * 2021-08-25 2023-03-02 Qiaojun HE Aromatic heterocyclic compound, pharmaceutical composition containing the same, and use thereof
CN116410211A (zh) * 2021-12-29 2023-07-11 山东新时代药业有限公司 一种苯并呋喃类化合物
WO2023138674A1 (zh) * 2022-01-21 2023-07-27 默达药物(香港)有限公司 N-羟基喹啉甲酰胺化合物及其用途
US20230391786A1 (en) * 2022-06-02 2023-12-07 Eli Lilly And Company cGAS INHIBITORS
AU2024387082A1 (en) 2023-11-21 2026-06-04 Fmc Corporation Substituted tetrahydroquinoline and tetrahydroquinoxaline herbicides
TW202542135A (zh) 2024-01-17 2025-11-01 南韓商Lg化學股份有限公司 作為CBP/p300抑制劑之新穎化合物和含有彼作為活性成分以預防或治療癌症、發炎病症或自體免疫疾病之醫藥組成物
KR20250113346A (ko) 2024-01-17 2025-07-25 주식회사 엘지화학 CBP/p300 저해제로 사용되는 신규 화합물, 및 이를 유효성분으로 포함하는 암, 염증성 장애 또는 자가면역 질환의 예방 또는 치료용 약학 조성물
CN122535608A (zh) 2024-01-17 2026-08-07 株式会社Lg化学 用作cbp/p300抑制剂的新型化合物以及包含其作为活性成分的用于预防或治疗癌症、炎性障碍或自身免疫性疾病的药物组合物
WO2026128761A1 (en) 2024-12-11 2026-06-18 Nexo Therapeutics, Inc. Covalent p300 inhibitor compounds

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2270143T3 (es) 2002-08-07 2007-04-01 Novartis Ag Compuestos organicos como agentes para el tratamiento de condiciones mediadas por aldosterona.
US20070004736A1 (en) 2002-11-22 2007-01-04 Keiji Kubo Imidazole derivative, process for producing the same, and use
WO2007139992A2 (en) 2006-05-26 2007-12-06 Novartis Ag ALDOSTERONE SYNTHASE AND/OR 11β-HYDROXYLASE INHIBITORS
US7943617B2 (en) * 2006-11-27 2011-05-17 Bristol-Myers Squibb Company Heterobicyclic compounds useful as kinase inhibitors
AU2007337659A1 (en) * 2006-12-22 2008-07-03 Actelion Pharmaceuticals Ltd. 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine derivatives
US8859538B2 (en) 2007-06-21 2014-10-14 Cara Therapeutics, Inc. Uses of substituted imidazoheterocycles
EA201000046A1 (ru) * 2007-06-21 2011-02-28 Кара Терапеутикс, Инк. Замещенные имидазогетероциклы
CN101417999A (zh) * 2007-10-25 2009-04-29 上海恒瑞医药有限公司 哌嗪类衍生物,其制备方法及其在医药上的应用
CN101468988A (zh) 2007-12-26 2009-07-01 上海恒瑞医药有限公司 哌嗪类衍生物,其制备方法及其在医药上的应用
KR20110036069A (ko) 2008-06-25 2011-04-06 액테리온 파마슈티칼 리미티드 5,6,7,8-테트라히드로-이미다조[1,5-a]피라진 화합물
PE20120121A1 (es) * 2008-12-08 2012-02-20 Gilead Connecticut Inc Derivados de imidazopirazina como inhibidores de syk
WO2011092120A1 (en) 2010-01-29 2011-08-04 Nerviano Medical Sciences S.R.L. 6,7- dihydroimidazo [1,5-a] pyrazin-8 (5h) - one derivatives as protein kinase modulators
CN102372716A (zh) * 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
WO2013050446A1 (en) 2011-10-07 2013-04-11 Nerviano Medical Sciences S.R.L. SUBSTITUTED 3,4-DIHYDROPYRROLO[1,2-a]PYRAZIN-1(2H)-ONE DERIVATIVES AS KINASES INHIBITORS
CN103087067A (zh) * 2012-08-02 2013-05-08 盛世泰科生物医药技术(苏州)有限公司 作为二肽基酶抑制剂的化合物及其组合物,以及它们的用途
WO2014062548A1 (en) 2012-10-18 2014-04-24 Bristol-Myers Squibb Company Tetrahydroimdidazopyrazine derivatives as cgrp receptor antagonists
CA2915163A1 (en) * 2013-06-12 2014-12-18 Proximagen Limited New therapeutic uses of enzyme inhibitors
HK1223364A1 (zh) * 2013-06-28 2017-07-28 Abbvie Inc. 布罗莫结构域抑制剂
CN107108512B (zh) 2014-10-10 2021-05-04 基因泰克公司 治疗性化合物及其用途
EP3632915A1 (en) * 2014-11-27 2020-04-08 Genentech, Inc. 4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors
MA41338B1 (fr) 2015-01-16 2019-07-31 Hoffmann La Roche Composés de pyrazine pour le traitement de maladies infectieuses
GB201506658D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
GB201506660D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
AU2017252276A1 (en) 2016-04-18 2018-11-15 Celgene Quanticel Research, Inc. Therapeutic compounds
WO2017205536A2 (en) * 2016-05-24 2017-11-30 Genentech, Inc. Therapeutic compounds and uses thereof
MA45146A (fr) * 2016-05-24 2021-03-24 Constellation Pharmaceuticals Inc Dérivés de pyrazolopyridine pour le traitement du cancer
CA3095367A1 (en) 2018-03-29 2019-10-03 Board Of Regents, The University Of Texas System Imidazopiperazine inhibitors of transcription activating proteins
WO2019195846A1 (en) 2018-04-06 2019-10-10 Board Of Regents, The University Of Texas System Imidazopiperazinone inhibitors of transcription activating proteins

Similar Documents

Publication Publication Date Title
JP2015534580A5 (cg-RX-API-DMAC7.html)
JP2016502504A5 (cg-RX-API-DMAC7.html)
FI3328827T3 (fi) Glutamiinianalogien aihiolääkkeitä
JP2017510641A5 (cg-RX-API-DMAC7.html)
JP2017186337A5 (cg-RX-API-DMAC7.html)
JP2018536624A5 (cg-RX-API-DMAC7.html)
JP2015534579A5 (cg-RX-API-DMAC7.html)
JP2017517506A5 (cg-RX-API-DMAC7.html)
MX338831B (es) Moduladores selectivos de receptores de androgenos.
WO2009105214A3 (en) Selective androgen receptor modulators
JP2020502271A5 (cg-RX-API-DMAC7.html)
WO2010118287A8 (en) Selective androgen receptor modulators
JP2018516966A5 (cg-RX-API-DMAC7.html)
JP2015527318A5 (cg-RX-API-DMAC7.html)
JP2014055156A5 (cg-RX-API-DMAC7.html)
JP2013523784A5 (cg-RX-API-DMAC7.html)
JP2019524714A5 (cg-RX-API-DMAC7.html)
AU2012288626A8 (en) 2 - (2, 4, 5 - substituted -anilino) pyrimidine derivatives as EGFR modulators useful for treating cancer
JP2017509586A5 (cg-RX-API-DMAC7.html)
JP2024519188A5 (cg-RX-API-DMAC7.html)
JP2023536504A5 (cg-RX-API-DMAC7.html)
JP2023542093A5 (cg-RX-API-DMAC7.html)
JP2019527239A5 (cg-RX-API-DMAC7.html)
JP2014532751A5 (cg-RX-API-DMAC7.html)
JP2015524414A5 (cg-RX-API-DMAC7.html)